Hillstone Networks Acknowledged as an XDR Leader in Frost Radar™ 2023 Report
13.9.2023 09:00:00 EEST | Business Wire | Press release
Hillstone Networks, a leading provider of cybersecurity solutions, has been named an innovation and growth leader in the 2023 Frost Radar™ Extended Detection and Response Report.
The Frost Radar™ 2023 Report is a market analysis conducted by Frost & Sullivan, evaluating industry participants based on their growth strategy, innovation, customer experience, and market share. The report aims to assist organizations in making informed decisions when selecting a reliable XDR solution provider.
“Our inclusion as a leader in the Frost Radar™ 2023 Report reaffirms our dedication to deliver cutting-edge solutions that effectively counter evolving digital threats,” states Tim Liu, CTO and Co-founder at Hillstone Networks. “Our solution integrates advanced threat detection, incident response, and forensic capabilities into a unified platform, empowering businesses to proactively safeguard their digital assets.”
According to Frost & Sullivan, XDR solutions have seen rapid expansion across geographies, industries, and companies of all sizes as it delivers the visibility, integration, analytics, flexibility, and automation that customers need in today’s complex IT environments. Frost states that XDR has three core promises: cross-layered detection and response, meaningful automation, and integration with the security stack.
"Hillstone Networks shows commitment to the Open XDR approach, as it is investing its significant R&D budget in increasing third-party integrations and providing software development kits (SDKs) to facilitate integration with its platform,” states Lucas Ferreyra, Industry Analyst at Frost & Sullivan. “Hillstone Networks has developed a compelling growth strategy, that involves leveraging the increasing relevance of managed security to allow MSSPs to use its XDR solution, broadening its reach while targeting high-growth sectors such as government, healthcare, education, and manufacturing. Such understanding of the market will allow Hillstone Networks to unlock further growth opportunities in the extremely competitive market of XDR.”
Hillstone’s commitment to continuous innovation and successful customer deployments contributes to its emergence as a frontrunner in the XDR domain, as well as delivering on the core promises of XDR:
- Hillstone’s AI-powered threat detection and response capabilities can find and mitigate attacks before they have a chance to exploit the most vital asset in the enterprise – data. The Hillstone XDR solution uses advanced machine learning (ML) algorithms through unknown malware and abnormal detection, advanced threat correlation analytics, and automatic threat mitigation.
- Hillstone XDR also includes automated orchestration and response. If a remediation strategy has been configured, once a threat is identified, Hillstone XDR will automatically execute the appropriate mitigation actions according to a predefined playbook.
- It includes integration with a wide variety of data across the full spectrum of the network, from endpoints to cloud. This data can include NetFlow, Sysmon, Syslogs, metadata, threat information and third-party logs, all of which are then standardized, correlated, and analyzed to provide complete visibility and break down security information silos. It not only brings full security visibility with far fewer blind spots, but also improves detection accuracy by minimizing false positives.
Learn more about Hillstone XDR here.
About Hillstone Networks
Hillstone Networks is a leader in cybersecurity, delivering both depth and breadth of protection to companies of all sizes, from edge to cloud, and across any workload. Hillstone Networks’ Integrative Cyber Security approach brings coverage, control, and consolidation to more than 26,000 enterprises worldwide. www.hillstonenet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912650308/en/
Contact information
Zeyao Hu
+1 4085086750
inquiry@hillstonenet.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
